Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...

Unquestionably, US drugmaker Vertex Pharmaceuticals is the dominant drug developer in the cystic fibrosis (CF) space. How has ...

The artificial intelligence (AI) boom has taken the stock market by storm. The S&P 500 (SNPINDEX: ^GSPC) has advanced 55% in ...

CWA Asset Management Group LLC trimmed its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) ...

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

Nordea Investment Management AB increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 19.4% during the fourth quarter, Holdings Channel reports. The ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $402.49, demonstrating a -1.13% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.55%. On ...

TreeFrog Therapeutics is making Cambridgeport Labs the site of its U.S. headquarters, leasing just under 13,500 square feet at the campus. The cell therapy biotech is moving to its own dedicated lab ...

Here’s a recap of key upgrades and downgrades affecting major stocks this week, focusing on analyst insights and market reactions. 1. American Airlines (NASDAQ: AAL) What Happened?Raymond James ...